New drug combo aims to keep aggressive myeloma at bay

NCT ID NCT06947083

Recruiting now Disease control Sponsor: H. Lee Moffitt Cancer Center and Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether the drug elranatamab, given as maintenance therapy after CAR-T cell treatment (cilta-cel), can delay cancer progression in people with high-risk relapsed myeloma. The study enrolls 39 patients whose myeloma has features like high-risk mutations or growth outside bones. Researchers will measure how long participants live without their myeloma worsening.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Elranatamab (a drug given as maintenance therapy after CAR-T cell treatment)
What this could lead to: If it works, this could help people with high-risk myeloma stay in remission longer after CAR-T therapy, delaying the return of the cancer.
What could go wrong: This is a small, early-phase study (39 people) with no control group, so results may not apply broadly. Elranatamab can cause side effects like infections or immune reactions, and the benefit over standard care is unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELOMA

Contacts and locations

Locations

Moffitt Cancer Center
RECRUITING

Tampa, Florida, 33612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.